Efficacy and Tolerability of Travoprost 0.004/Timolol 0.5 Fixed-Dose Combination for the Treatment of Primary Open-Angle Glaucoma or Ocular Hypertension Inadequately Controlled with Beta-Blocker Monotherapy

Table 3

Incidence of treatment-related TEAEs during the study (safety population).

MedDRA preferred term	TTFC; ()	Beta-blocker; ()
Eye disorders, n (%)	12 (14.8)	3 (4.0)
Ocular hyperemia	5 (6.2)	0
Ocular pruritus	3 (3.7)	0
Conjunctivitis allergic	1 (1.2)	1 (1.3)
Dry eye	1 (1.2)	1 (1.3)
Ocular surface disease	1 (1.2)	1 (1.3)
Eyelid-pigmentation	1 (1.2)	0
Eye irritation	1 (1.2)	0
Eye pain	1 (1.2)	0
Eyelids pruritus	1 (1.2)	0
Immune system disorders, n (%)	1 (1.2)
Hypersensitivity	1 (1.2)	0

A subject with more than one event in a specific category was only counted once. MedDRA coding; due to splitting of terms, number of MedDRA terms can be different from number of reported events. MedDRA version 18.0.
MedDRA, Medical Dictionary for Regulatory Activities; TEAEs, treatment-emergent adverse events; TTFC, travoprost 0.004%/timolol 0.5% fixed-dose combination.